Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
Mirum Pharmaceuticals announced its participation in the NASPGHAN annual meeting (November 6-9, 2024) in Hollywood, Florida, where it will present LIVMARLI® (maralixibat) data for Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) treatments. The presentations will showcase clinical benefits and real-world evidence, including improvements in growth for PFIC patients, 7-year durability of benefits in ALGS patients, liver health improvements, enhanced quality of life, and impact on concomitant medication use for cholestatic pruritus treatment.
Mirum Pharmaceuticals ha annunciato la sua partecipazione alla riunione annuale NASPGHAN (6-9 novembre 2024) a Hollywood, in Florida, dove presenterà i dati di LIVMARLI® (maralixibat) per le terapie della sindrome di Alagille (ALGS) e della colestasi intraepatica familiare progressiva (PFIC). Le presentazioni metteranno in evidenza i benefici clinici e le evidenze del mondo reale, inclusi miglioramenti nella crescita dei pazienti con PFIC, durevolezza dei benefici per 7 anni nei pazienti con ALGS, miglioramenti nella salute epatica, una qualità della vita migliorata e l'impatto sull'uso di farmaci concomitanti per il trattamento del prurito colestatico.
Mirum Pharmaceuticals anunció su participación en la reunión anual de NASPGHAN (del 6 al 9 de noviembre de 2024) en Hollywood, Florida, donde presentará datos de LIVMARLI® (maralixibat) para el tratamiento del síndrome de Alagille (ALGS) y la colestasis intrahepática familiar progresiva (PFIC). Las presentaciones destacarán los beneficios clínicos y la evidencia del mundo real, incluyendo mejoras en el crecimiento de pacientes con PFIC, durabilidad de los beneficios de 7 años en pacientes con ALGS, mejoras en la salud hepática, una calidad de vida mejorada y el impacto en el uso de medicamentos concomitantes para el tratamiento del prurito colestático.
미럼 제약회사는 2024년 11월 6일부터 9일까지 플로리다 주 할리우드에서 열리는 NASPGHAN 연례회의에 참여한다고 발표했습니다. 이 회의에서 LIVMARLI® (마랄리키밧) 치료 데이터를 알라질 증후군(ALGS) 및 진행성 가족성 간내 담즙 정체(PFIC) 치료에 대해 발표할 예정입니다. 발표에서는 PFIC 환자의 성장 개선, ALGS 환자에서의 7년 동안의 혜택 지속성, 간 건강 개선, 삶의 질 향상, 담즙 가려움증 치료를 위한 동반 약물 사용에 대한 영향 등 임상적 혜택과 실제 데이터가 강조될 것입니다.
Mirum Pharmaceuticals a annoncé sa participation à la réunion annuelle de la NASPGHAN (du 6 au 9 novembre 2024) à Hollywood, en Floride, où elle présentera des données sur LIVMARLI® (maralixibat) pour les traitements du syndrome d'Alagille (ALGS) et de la cholestase intra-hépatique familiale progressive (PFIC). Les présentations mettront en avant les bénéfices cliniques et les preuves du monde réel, y compris les améliorations de la croissance pour les patients atteints de PFIC, la durabilité des bénéfices sur 7 ans chez les patients atteints d'ALGS, les améliorations de la santé hépatique, la qualité de vie améliorée et l'impact sur l'utilisation de médicaments concomitants pour le traitement du prurit cholestatique.
Mirum Pharmaceuticals gab seine Teilnahme am jährlichen NASPGHAN-Treffen (6. bis 9. November 2024) in Hollywood, Florida, bekannt, wo das Unternehmen Daten zu LIVMARLI® (maralixibat) für die Behandlung des Alagille-Syndroms (ALGS) und der progressiven familiären intrahepatischen Cholestase (PFIC) präsentieren wird. In den Präsentationen werden klinische Vorteile und reale Beweise vorgestellt, darunter Wachstumsverbesserungen bei PFIC-Patienten, 7-jährige Haltbarkeit der Vorteile bei ALGS-Patienten, Verbesserungen der Lebergesundheit, verbesserte Lebensqualität und Einfluss auf die gleichzeitige Medikation zur Behandlung von cholestatischem Pruritus.
- Clinical benefits of LIVMARLI shown to be durable through 7 years of treatment in ALGS patients
- Demonstrated improvements in growth for PFIC patients
- Data shows improvements in liver health markers
- Evidence of enhanced quality of life for patients
- Positive real-world impact on treatment of cholestatic pruritus
- None.
Highlighted below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the NASPGHAN Program Book. Full analyses will be available following their presentation within the Publications & Presentations section on Mirum’s website.
Abstract 77: Maralixibat improves growth in patients with progressive familial intrahepatic cholestasis: Data from the MARCH/MARCH-ON trials
Thursday, November 7 between 5:00-7:00 p.m. ET during Poster Session I
Presented by Dr. Amal Aqul
Abstract 361: Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: Data from the MERGE study
Friday, November 8 between 12:00-2:00 p.m. ET during Poster Session II
Presented by Dr. Karen Murray
Abstract 637: Improvements in serum bile acids are associated with improvements in markers of liver health after maralixibat treatment in children with PFIC: Data from the MARCH/MARCH-ON trials
Saturday, November 9 between 12:00-2:00 p.m. ET during Poster Session III
Presented by Dr. Alexander Miethke
Abstract 638: Improvements in pruritus after maralixibat treatment are associated with improved health-related quality of life for patients with cholestatic liver disease
Saturday, November 9 between 12:00-2:00 p.m. ET during Poster Session III
Presented by Dr. Alexander Miethke
Abstract 664: Long-term maralixibat impact on concomitant medication use for the treatment of cholestatic pruritus in Alagille syndrome: Real-world experience in
Saturday, November 9 between 12:00-2:00 p.m. ET during Poster Session III
Presented by Dr. Jolan Terner-Rosenthal
About LIVMARLI® (maralixibat) oral solution
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the
LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS and PFIC. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.
IMPORTANT SAFETY INFORMATION
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.
LIVMARLI can cause side effects, including:
Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.
US Prescribing Information
EU SmPC
Canadian Product Monograph
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Forward-Looking Statements
This press release includes forward-looking statements pertaining to the Company’s planned participation at a scientific conference, including data presentation title and synopsis, which may include discussion of the Company’s clinical and research data relating to the therapeutic potential and/or commercial viability of LIVMARLI in various liver disease indications and in patient populations that are investigational only. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “could,” “would,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. A further description of risks and uncertainties can be found in Mirum’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors,” as well as in its subsequent reports on Form 8-K, all of which are filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031636363/en/
Media Contact:
Erin Murphy
media@mirumpharma.com
Investor Contact:
Andrew McKibben
ir@mirumphama.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
What data will Mirum Pharmaceuticals (MIRM) present at NASPGHAN 2024?
How long does LIVMARLI's effectiveness last in ALGS patients according to MIRM's MERGE study?